{"id":"NCT02361944","sponsor":"Vanderbilt University","briefTitle":"Risk of Oxygen During Cardiac Surgery Trial","officialTitle":"Risk of Oxygen During Cardiac Surgery (ROCS) Trial","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2016-04-05","primaryCompletion":"2020-10-08","completion":"2021-01-08","firstPosted":"2015-02-12","resultsPosted":"2023-08-14","lastUpdate":"2024-02-01"},"enrollment":213,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Cardiac Surgery"],"interventions":[{"type":"DRUG","name":"Oxygen - normoxia","otherNames":["oxygen"]},{"type":"DRUG","name":"Oxygen - hyperoxia","otherNames":["oxygen"]}],"arms":[{"label":"Normoxia","type":"EXPERIMENTAL"},{"label":"Hyperoxia","type":"ACTIVE_COMPARATOR"}],"summary":"The investigators will recruit and randomize 200 elective cardiac surgery patients to receive physiologic oxygenation (normoxia) or hyper-oxygenation (hyperoxia) during surgery to test the hypothesis that intraoperative physiologic oxygenation decreases the generation of reactive oxygen species, oxidative damage, and postoperative organ injury compared to hyper-oxygenation.","primaryOutcome":{"measure":"Intraoperative Systemic Oxidative Damage","timeFrame":"separation from cardiopulmonary bypass or completion of off-pump coronary artery bypass grafting (approximately 3-5 hours into surgery and intervention)","effectByArm":[{"arm":"Normoxia","deltaMin":69,"sd":null},{"arm":"Hyperoxia","deltaMin":83,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":8},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["40673571","39110454","28651648"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":100},"commonTop":["Anemia","Leukocytosis","Vasoplegia","Hypotension","Fever"]}}